Loading
Latest filing published 19 Jan 2022 for Entasis Therapeutics Holdings Inc.. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Michael Gutch is a declared insider of Entasis Therapeutics Holdings Inc., with filings sourced from SEC (Form 4). We count 3 filings; the first trade dates from 19 October 2021 and the latest from 18 January 2022.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
On 19 January 2022 came the latest disclosure, a share grant in Entasis Therapeutics Holdings Inc. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. Section 16 rules allow two business days to file each Form 4. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
3 of 3 declarations